| Therapeutic | Camrelizumab |
| Target | PDCD1 |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Chinese PLA General Hospital%3BHangzhou Cancer Hospital%3BIncyte Corporation%3BJiangsu Hengrui Medicine Co.%3BNanjing Medical University%3BPeking University People%27s Hospital%3BSun Yat-Sen University |
| Conditions Approved | Hodgkin%27s disease |
| Conditions Active | Nasopharyngeal cancer%3BNon-small cell lung cancer%3BOesophageal cancer%3BLiver cancer%3BBiliary cancer%3BCervical cancer%3BCholangiocarcinoma%3BColorectal cancer%3BEndometrial cancer%3BFallopian tube cancer%3BGastric cancer%3BOsteosarcoma%3BOvarian cancer%3BPancreatic cancer%3BPeritoneal cancer%3BRenal cell carcinoma%3BSolid tumours%3BUrogenital cancer%3BDiffuse large B cell lymphoma%3BBreast cancer%3BMalignant melanoma |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
